Onvansertib
CRDF-001
Phase 2 small_molecule completed
Quick answer
Onvansertib for Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at Cardiff Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cardiff Oncology
- Indication
- Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed